Skip Navigation

Cardiovascular Research 2004 64(1):32-39; doi:10.1016/j.cardiores.2004.06.003
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Cascorbi, I.
Right arrow Articles by Kroemer, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cascorbi, I.
Right arrow Articles by Kroemer, H. K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Pharmacogenomics of heart failure - focus on drug disposition and action*

Ingolf Cascorbia, Martin Paulb and Heyo K. Kroemer*,a

aDepartment of Pharmacology, Peter Holtz Research Center of Pharmacology and Experimental Therapeutics, Ernst Moritz Arndt University, Greifswald, Germany
bInstitute of Clinical Pharmacology and Toxicology, Charité-University Medicine Berlin, Charité Campus Benjamin Franklin, Germany

* Corresponding author. Institute of Pharmacology, University of Greifswald, Friedrich-Loeffler-Str. 23d, D-17489, Greifswald, Germany. Tel.: +49-3834-865630; fax: +49-3834-865631. E-mail address: kroemer{at}uni-greifswald.de

Heart failure represents the composite endpoint of various cardiovascular disorders. Advanced pharmacotherapy resulted in significant improvement of overall survival, however with highly variable outcome, possibly due to genetic modification of drug disposition and action. This review highlights the role of genetic polymorphisms in systems responsible for disposition of drugs, used in heart failure patients (e.g. the polymorphic drug metabolizing enzymes such as cytochrome P450 enzymes, as well as polymorphic ATP-membrane transporters like P-glycoprotein (P-gp)). In addition, genetic variants in physiological systems, being target of drug action, particularly beta-adrenergic receptors, the renin–angiotensin–aldosterone system (RAAS)- and endothelin system, and the endothelial nitrogene monoxide (NO) synthase are reviewed. The current situation in pharmacogenomics of heart failure with respect to drug disposition and action is characterized by multiple studies investigating single components of a complex system. Therefore, overall conclusions regarding treatment and/or outcome of heart failure patients based on individual genetic traits require large prospective trials allowing for simultaneous assessment of multiple genetic variants in different systems. Using advanced screening technologies, such trials can be carried out in the near future.

KEYWORDS Heart failure; Gene polymorphism; Pharmacokinetics; Adrenergic antagonists; Renin–angiotensin system

Gerd Hasenfuss, University of Göttingen, served as Guest Editor for October.

Time for primary review 15 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.